Anyone got any health problems after the HPV vaccination ?

Contact “TimeForAction”, a campaign group run by UK families for UK families

My daughter has developed health problems after receiving the Gardasil vaccine, what should I do ?

If your daughter has developed health problems after HPV vaccination, please get in touch with TimeForAction – a campaign group run by UK families for UK families. They’re campaigning hard to ensure that these health problems are properly acknowledged and investigated, that families are treated with compassion and respect within the health service and that there is educational support in place for the girls who are struggling to attend school on a full timetable.

TimeForAction is also calling for a full disclosure of all the potential risks associated with the HPV vaccination to be given to parents when seeking consent, in conjunction with a more accurate assessment of the stated benefits. For more information, visit TimeForAction website, call 07885 422690, email, tweet or use this form.

HPV vaccination not recommended by 1/3 of doctors

Primary Care Physicians’ Perspectives About HPV Vaccine

Around one third of doctors surveyed do not strongly recommend the HPV vaccine to parents. Researchers used a national survey asking approximately 600 paediatricians and family doctors, between October 2013 and January 2014, to outline their stance on the HPV vaccine.

January 2016 Study Abstract

Because physicians’ practices could be modified to reduce missed opportunities for human papillomavirus (HPV) vaccination, our goal was to:

  1. describe self-reported practices regarding recommending the HPV vaccine;
  2. estimate the frequency of parental deferral of HPV vaccination;
  3. and identify characteristics associated with not discussing it.

A national survey among pediatricians and family physicians (FP) was conducted between October 2013 and January 2014. Using multivariable analysis, characteristics associated with not discussing HPV vaccination were examined.

Response rates were 82% for pediatricians (364 of 442) and 56% for FP (218 of 387).

  • For 11-12 year-old girls, 60% of pediatricians and 59% of family physicians (FP) strongly recommend HPV vaccine; for boys,52% and 41% ostrongly recommen.
  • More than one-half reported ≥25% of parents deferred HPV vaccination.
  • At the 11-12 year well visit, 84% of pediatricians and 75% of FP frequently/always discuss HPV vaccination.
  • Compared with physicians who frequently/always discuss , those who occasionally/rarely discuss(18%) were more likely to be FP (adjusted odds ratio [aOR]: 2.0 [95% confidence interval (CI): 1.1–3.5), be male (aOR: 1.8 [95% CI: 1.1–3.1]), disagree that parents will accept HPV vaccine if discussed with other vaccines (aOR: 2.3 [95% CI: 1.3–4.2]), report that 25% to 49% (aOR: 2.8 [95% CI: 1.1–6.8]) or ≥50% (aOR: 7.8 [95% CI: 3.4–17.6]) of parents defer, and express concern about waning immunity (aOR: 3.4 [95% CI: 1.8–6.4]).

Addressing physicians’ perceptions about parental acceptance of HPV vaccine, the possible advantages of discussing HPV vaccination with other recommended vaccines, and concerns about waning immunity could lead to increased vaccination rates.

Sources and Press Releases
  • Primary Care Physicians’ Perspectives About HPV Vaccine, pediatrics, January 2016.

Vaccins: un biologiste dénonce la désinformation

Vaccinations – Les vérités indésirables

Vidéo publiée le 13 avril 2009 par la chaîne Expovaccins.

Ecoutez Michel Georget faire une analogie entre le gardasil et le distilbène…

Le Distilbène DES, en savoir plus

La vaccination inutile et le racket des laboratoires pharmaceutiques

Invité du jour: Serge Rader, lanceur d’alerte

Vidéo publiée le 18 janvier 2016 par TV Libertés.

Aujourd’hui le calendrier vaccinal pose des soucis, et la balance bénéfices/risques semble peser très lourd sur le plateau des risques…

  • Auteur du livre “Le racket des laboratoires pharmaceutiques : et comment s’en sortir” Serge Rader, pharmacien durant de très nombreuses années et depuis peu lanceur d’alertes met en lumière, au travers de cas concrets, les dangers de la vaccination.
  • Nos liste de vidéos sur les médicaments et labos.

Débat : médicaments, l’overdose?

L’industrie pharmaceutique et le milieu médical, 2015

Débat Grand Ecran présenté par Emilie Aubry, via LCP, avec :

  • Jean de Kervasdoué, professeur, économiste de la Santé
  • Yann Philippin, grand reporter, journaliste
En Savoir Plus
LA Campagne de Médecins du monde

Ovarian failure caused by Gardasil HPV vaccine ?

2012-2014 studies on the association between human papillomavirus vaccine and adolescent primary ovarian failure

Adolescent Premature Ovarian Insufficiency Following Human Papillomavirus Vaccination

2014 Study Abstract

Adolescent Premature Ovarian Insufficiency Following Human Papillomavirus Vaccination, National Institutes of Health, NCBI pmc/articles/PMC4528880/, 2014 Oct-Dec.

Three young women who developed premature ovarian insufficiency following quadrivalent human papillomavirus (HPV) vaccination presented to a general practitioner in rural New South Wales, Australia. The unrelated girls were aged 16, 16, and 18 years at diagnosis. Each had received HPV vaccinations prior to the onset of ovarian decline. Vaccinations had been administered in different regions of the state of New South Wales and the 3 girls lived in different towns in that state. Each had been prescribed the oral contraceptive pill to treat menstrual cycle abnormalities prior to investigation and diagnosis. Vaccine research does not present an ovary histology report of tested rats but does present a testicular histology report. Enduring ovarian capacity and duration of function following vaccination is unresearched in preclinical studies, clinical and postlicensure studies. Postmarketing surveillance does not accurately represent diagnoses in adverse event notifications and can neither represent unnotified cases nor compare incident statistics with vaccine course administration rates. The potential significance of a case series of adolescents with idiopathic premature ovarian insufficiency following HPV vaccination presenting to a general practice warrants further research. Preservation of reproductive health is a primary concern in the recipient target group. Since this group includes all prepubertal and pubertal young women, demonstration of ongoing, uncompromised safety for the ovary is urgently required. This matter needs to be resolved for the purposes of population health and public vaccine confidence.

Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants

2013 Study Abstract

Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants, American journal of reproductive immunology New York, NCBI pubmed/23902317, 2013 Jul 31.

Post-vaccination autoimmune phenomena are a major facet of the autoimmune/inflammatory syndrome induced by adjuvants (ASIA) and different vaccines, including HPV, have been identified as possible causes.

The medical history of three young women who presented with secondary amenorrhea following HPV vaccination was collected. Data regarding type of vaccine, number of vaccination, personal, clinical and serological features, as well as response to treatments were analyzed.

All three patients developed secondary amenorrhea following HPV vaccinations, which did not resolve upon treatment with hormone replacement therapies. In all three cases sexual development was normal and genetic screen revealed no pertinent abnormalities (i.e., Turner’s syndrome, Fragile X test were all negative). Serological evaluations showed low levels of estradiol and increased FSH and LH and in two cases, specific auto-antibodies were detected (antiovarian and anti thyroid), suggesting that the HPV vaccine triggered an autoimmune response. Pelvic ultrasound did not reveal any abnormalities in any of the three cases. All three patients experienced a range of common non-specific post-vaccine symptoms including nausea, headache, sleep disturbances, arthralgia and a range of cognitive and psychiatric disturbances. According to these clinical features, a diagnosis of primary ovarian failure (POF) was determined which also fulfilled the required criteria for the ASIA syndrome.

We documented here the evidence of the potential of the HPV vaccine to trigger a life-disabling autoimmune condition. The increasing number of similar reports of post HPV vaccine-linked autoimmunity and the uncertainty of long-term clinical benefits of HPV vaccination are a matter of public health that warrants further rigorous inquiry.

Premature ovarian failure 3 years after menarche in a 16-year-old girl following human papillomavirus vaccination

2012 Study Abstract

Premature ovarian failure 3 years after menarche in a 16-year-old girl following human papillomavirus vaccination, BMJ Case Report, NCBI pmc/articles/PMC4543769, 2012 Sep 30.

Premature ovarian failure in a well adolescent is a rare event. Its occurrence raises important questions about causation, which may signal other systemic concerns. This patient presented with amenorrhoea after identifying a change from her regular cycle to irregular and scant periods following vaccinations against human papillomavirus. She declined the oral contraceptives initially prescribed for amenorrhoea. The diagnostic tasks were to determine the reason for her secondary amenorrhoea and then to investigate for possible causes of the premature ovarian failure identified. Although the cause is unknown in 90% of cases, the remaining chief identifiable causes of this condition were excluded. Premature ovarian failure was then notified as a possible adverse event following this vaccination. The young woman was counselled regarding preservation of bone density, reproductive implications and relevant follow-up. This event could hold potential implications for population health and prompts further inquiry.

2017 Update

Premature Ovarian Insufficiency – an update on recent advances in understanding and management

2017 Study Abstract

Premature ovarian insufficiency is a complex and relatively poorly understood entity with a myriad of etiologies and multisystem sequelae that stem from premature deprivation of ovarian sex hormones. Timely diagnosis with a clear understanding of the various comorbidities that can arise from estrogen deficiency is vital to appropriately counsel and treat these patients. Prompt initiation of hormone therapy is critical to control the unsolicited menopausal symptoms that many women experience and to prevent long-term health complications. Despite ongoing efforts at improving our understanding of the mechanisms involved, any advancement in the field in recent decades has been modest at best and researchers remain thwarted by the complexity and heterogeneity of the underpinnings of this entity. In contrast, the practice of clinical medicine has made meaningful strides in providing assurance to the women with premature ovarian insufficiency that their quality of life as well as long-term health can be optimized through timely intervention. Ongoing research is clearly needed to allow pre-emptive identification of the at-risk population and to identify mechanisms that if addressed in a timely manner, can prolong ovarian function and physiology.

Read the full study (free access) on the NCI PubMed, PMCID: PMC5710309.

Less than Half of Girls get the HPV Vaccine in the U.S.: 2014 CDC Data

Very few kids are getting vaccinated for HPV in the United States…

National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2014, cdc, July 31, 2015.

According to the Centers for Disease Control and Prevention, as of 2014, only 40 percent of girls ages 13 to 17 had completed the three-vaccine course of HPV immunization. This is well below the 80 percent goal set in 2010 by the federal government in its Healthy People 2020 report.

Why Are So Few Kids Getting the HPV Vaccine?, pewtrusts, April 07, 2016.

Despite media marketing – claiming it might save lives since it is targeting cervical cancer – and medical efforts to raise vaccination rates, public health officials say that for a variety of reasons, parents and doctors have not embraced the HPV vaccine.

Some states have much lower rates ; in Tennessee, for example, the vaccination rate for girls was 20 percent. The higher rate reported is North Carolina with 54%.

” The HPV vaccine is extremely controversial. There are hundreds of reports of injury and even death from this vaccine. This vaccine has never been proven safe or effective. The trials for it never ran long enough to prove that it actually works. The other problem is it only supposedly protects you from 2 of the 6 viruses that can cause HPV. “

Read the comments left here and our posts tagged Gardasil

Aluminium et vaccins : les chercheurs nous alertent

Des chercheurs internationaux témoignent sur la toxicité de l’aluminium dans les vaccins

Le 22 mai 2014, des scientifiques du monde entier se sont rassemblés à l’Assemblée Nationale Française pour le colloque : “Aluminium et vaccins : l’expertise internationale nous impose d’agir”.

Sur le même sujet

European Medicines Agency started reviewing HPV vaccines safety

EMA confirmed evidence does not support that HPV vaccines cause CRPS or POTS… but the Nordic Cochrane Center said their report is flawed…

image of hpv-vaccine
Concerned by reports of serious adverse effects in young women receiving human papillomavirus (HPV) vaccines, the European Medicines Agency started a safety review. Three HPV vaccines are currently licensed in Europe: Gardasil/Silgard, Gardasil 9, and Cervarix, all of which are approved in the U.S. as well.

July 2015

The European Medicines Agency (EMA) started a review of HPV vaccines to further clarify aspects of their safety profile.

The review looked at available data with a focus on rare reports of two conditions:

  • complex regional pain syndrome (CRPS)
    a chronic pain condition affecting the limbs,
  • postural orthostatic tachycardia syndrome (POTS)
    a condition where the heart rate increases abnormally after sitting or standing up, causing symptoms such as dizziness and fainting, as well as headache, chest pain and weakness.

In its review the agency’s Pharmacovigilance Risk Assessment Committee (PRAC) considered the latest scientific knowledge, including any research that could help clarify the frequency of CRPS and POTS following vaccination or identify any causal link. Based on this review, the Committee decided whether to recommend any changes to product information to better inform patients and healthcare professionals.

November 2015

EMA concluded this review : HPV vaccines: EMA confirms evidence does not support that they cause CRPS or POTS.

Summer 2016

An official complaint has been filed by the Nordic Cochrane Center against the European Medicines Agency (EMA) over its handling of safety issues concerning human papillomavirus (HPV) vaccines.

In the complaint, which runs to 19 pages, the Nordic group says that the official EMA report is flawed.

  • Complaint to the European Medicines Agency (EMA) over maladministration at the EM, Nordic Cochrane Centre, 26 May 2016.
  • Complaint Filed Over EMA’s Handling of HPV Vaccine Safety Issues, Medscape Medical News, July 05, 2016.

Gardasil: va-t-on vers un nouveau scandale de santé publique?

Gardasil: des bénéfices supérieurs aux risques?

Entretien avec Claire Séverac autour du vaccin Gardasil et de son livre, “Complot mondial contre la santé”.

En savoir plus